Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Galmed Pharmaceuticals (NASDAQ:GLMD) stock has reached a 52-week low, touching down at $1.32, representing a stark 94% decline from its 52-week high of $23.80. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value calculations, despite facing a challenging period marked by investor concerns and broader market pressures. This latest price level reflects a significant downturn, with the stock plummeting 63% over the past year. InvestingPro data reveals concerning fundamentals, including negative EBITDA of -$6.2M and a current market capitalization of just $2.05M. The decline to this year’s low underscores the hurdles Galmed has encountered, with InvestingPro analysts noting the company is not expected to be profitable this year. Discover 11 more exclusive InvestingPro Tips for GLMD by subscribing today.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.